Kenalog® Spray and Halog® Cream:
New insights and implications for better compliance

A 1-hour Webinar with Live Q & A:
Wednesday, September 10th, 7 p.m. EDT

(also available on demand after broadcast)

Join us for an educational webinar featuring Dr. Zoe Draelos, Dermatology Times
editorial advisory board member and renowned clinical and research dermatologist,
who will be discussing important new data from Phase IV clinical studies of Kenalog®
Spray (Triamcinolone Acetonide Topical Aerosol, USP) 0.147 mg/g and Halog® (Halcinonide, USP) 0.1% Cream.

In this program you'll learn about:
• the efficacy of Kenalog® Spray when using a No-Touch technique
• the sustained release characteristics of Halog® cream

HALOG® is a registered trademark of Ranbaxy Laboratories Inc.
Kenalog® is a licensed trademark of Bristol-Myers Squibb Company.
Funding and content provided by Ranbaxy Laboratories Inc.